Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2020 Sep 30. doi: 10.1111/bjd.19574.
PMID: 33000465


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016